Novo Nordisk Inc v. Orbicular Pharmaceutical Tech Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Sun Pharmaceutical Industries Ltd. (India) and Sun Pharmaceutical Industries, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:22-cv-00856, D. Del., 05/31/2023
• Venue Allegations: Venue is alleged to be proper in the District of Delaware based on Defendant Sun Pharmaceutical Industries, Inc. being a Delaware corporation and both defendants conducting business in the state, including an intention to sell the accused product in the district.
• Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) seeking to market a generic version of the drug Saxenda® infringes three U.S. patents related to the mechanics of the drug delivery injection device.
• Technical Context: The technology at issue involves mechanical features of pen-style injection devices used for self-administration of medications, focusing on dose-limiting safety mechanisms and user-interface components like injection buttons.
• Key Procedural History: This action arises under the Hatch-Waxman Act following Defendant's submission of ANDA No. 216477 with a Paragraph IV certification, alleging that Plaintiff's patents are invalid, unenforceable, or will not be infringed. This First Amended Complaint is part of a consolidated ANDA case and follows prior notice letters sent by Defendant to Plaintiff. The complaint notes that a number of previously asserted patents have been dismissed from the current action.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,920,383 - "Dose Mechanism for an Injection Device for Limiting a Dose Setting Corresponding to the Amount of Medicament Left"

The Invention Explained

• Problem Addressed: The patent addresses the problem of preventing a user of a multi-dose injection pen from setting a dose that is larger than the amount of medication remaining in the device's reservoir Compl. ¶33 '383 Patent, col. 1:20-27 This prevents a patient from receiving an incomplete dose.
• The Patented Solution: The invention is a mechanical dose-limiting system comprising a threaded piston rod, a "limiter," and a "driver" Compl. ¶33 During each dose setting, relative rotation between the driver and the piston rod causes the limiter to move incrementally along the piston rod toward a stopping position '383 Patent, col. 2:5-17 Once the total set doses cause the limiter to reach this stopping position, it physically prevents the user from setting a dose that exceeds the remaining volume, thereby providing an "accumulative" end-of-content stop '383 Patent, col. 1:63-67
• Technical Importance: This mechanism provides a critical safety feature for reusable injection pens, ensuring users are aware when the cartridge is nearly empty and cannot accidentally set a dose they cannot fully receive Compl. ¶33

Key Claims at a Glance

• The complaint asserts claims 1-13 Compl. ¶33
• Independent claim 1 includes the following essential elements:
  • A piston rod with a threaded outer surface.
  • A limiter that is rotationally fixed to the piston rod and has its own threaded outer surface.
  • A driver coupled to the dose setting member, which has a threaded inner surface that engages the limiter's threaded outer surface.
  • Wherein relative rotation between the driver and the piston rod during dose setting causes the limiter to move towards a stopping position that prevents setting an excessive dose.

U.S. Patent No. 9,775,953 - "Dose Mechanism for an Injection Device for Limiting a Dose Setting Corresponding to the Amount of Medicament Left"

The Invention Explained

• Problem Addressed: The patent addresses the same problem as the '383 Patent-preventing a user from setting a dose greater than the remaining medicament-and further seeks to provide a redundant safety system in case the primary dose-limiting mechanism fails '953 Patent, col. 4:1-5
• The Patented Solution: The invention adds a "safety mechanism" that acts as a backup to the primary "dose limiting mechanism" '953 Patent, abstract If the primary mechanism (e.g., stopping surfaces on a dose drum) fails, the safety mechanism, which involves a hard stop between the limiter and a piston rod guide, is designed to prevent ejection of a dose exceeding the set dose '953 Patent, col. 4:1-6 '953 Patent, col. 5:64-67 The patent describes this as providing "an extra safety for the patient" '953 Patent, col. 4:63-65
• Technical Importance: By incorporating a redundant safety feature, the invention enhances patient safety against accidental overdose resulting from a mechanical failure in the primary dose-limiting components of an injection pen '953 Patent, col. 4:1-5

Key Claims at a Glance

• The complaint asserts claims 1-25 Compl. ¶39
• Independent claim 1 includes the following essential elements:
  • A syringe device with a housing and a dose ejecting mechanism (including a dose setting member and a piston rod).
  • A dose limiting mechanism operably connected with the dose ejecting mechanism to prevent ejection of a dose exceeding the set dose.
  • A safety mechanism structure, also connected to the dose ejecting mechanism, which prevents ejection of a dose exceeding the set dose if the dose limiting mechanism fails.

U.S. Patent No. 9,265,893 - "Injection Button"

The Invention Explained

• Technology Synopsis: The patent describes a specific mechanical connection between the push button that a user presses and the internal driving part that expels the medication. The invention uses a "pivot bearing" to form the contact point, which is designed to minimize rotational friction that occurs when the driving part rotates relative to the non-rotating push button during injection, thereby reducing the force a user must apply '893 Patent, abstract '893 Patent, col. 2:40-52

Key Claims at a Glance

• Asserted Claims: The complaint asserts at least exemplary claim 1 Compl. ¶45
• Accused Features: The complaint accuses the push button connection in "Sun's Device" of infringing, alleging it contains a push button, a relatively rotatable driving part, and a pivot bearing as claimed Compl. ¶¶46-53

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Sun's Product," a generic version of the Saxenda® (liraglutide) injection solution, which is delivered using "Sun's Device" Compl. ¶1 Compl. ¶26

Functionality and Market Context

Sun's Device is identified as a device for patients to self-administer a generic liraglutide formulation via subcutaneous injection Compl. ¶26 The complaint alleges that Sun's ANDA submission (No. 216477) seeks FDA approval to market this product as a generic equivalent to Novo Nordisk's Saxenda® product, relying on the Saxenda® New Drug Application to demonstrate bioequivalence Compl. ¶¶21-22 The complaint includes a redacted image described as an exemplary schematic of Sun's Device taken from the ANDA submission Compl. ¶29

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart exhibit for any of the asserted patents. For the '383 and '953 patents, the complaint makes only general allegations of infringement without detailing a specific infringement theory Compl. ¶33 Compl. ¶39

For the '893 patent, the complaint provides a narrative infringement theory, but the paragraphs detailing the specific components of Sun's Device are heavily redacted, precluding a summary in a claim chart format Compl. ¶¶47-53 The complaint alleges, on information and belief, that Sun's Device literally or equivalently meets every limitation of at least claim 1 of the '893 patent Compl. ¶46 The unredacted portions of the allegations indicate that components of Sun's Device are mapped to claim elements such as the "push button," "driving part," "bore," "protrusion," and "pivot bearing" Compl. ¶¶47-53

Identified Points of Contention

• Evidentiary Questions ('383 and '953 Patents): As the complaint provides no specific theory for the '383 and '953 patents, a primary area of dispute will be evidentiary. A question for the court will be whether the device described in Sun's ANDA contains the specific multi-component "limiter" and "driver" mechanisms that interact with a threaded "piston rod" in the manner required by the claims to limit dose setting, as well as the redundant "safety mechanism structure" claimed in the '953 Patent.
• Technical and Scope Questions ('893 Patent): Based on the narrative allegations, a central technical dispute may involve whether the interface between the push button and the driving part in Sun's Device functions as a "pivot bearing" as that term is understood in the patent. This raises a potential claim construction issue regarding the structural requirements of a "pivot bearing" and a factual question of whether the accused device's structure meets that definition.

V. Key Claim Terms for Construction

The Term: "limiter" (from '383 Patent, claim 1; '953 Patent, claim 7)

• Context and Importance: The "limiter" is the central component of the claimed end-of-dose mechanisms. The definition of this term-specifically its structure and its claimed interaction with the piston rod and driver-is critical to the infringement analysis for both the '383 and '953 patents. Practitioners may focus on this term because infringement depends on whether the accused device contains a component that both has the structure and performs the function of the claimed "limiter."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patents functionally describe the limiter as a component that "prevents setting of a dose which exceeds the amount of a medicament" '383 Patent, col. 2:14-17 A party may argue that any component performing this function via relative rotation could be considered a "limiter."
  • Evidence for a Narrower Interpretation: The specification discloses specific embodiments where the limiter is a distinct component with threads that engage both the piston rod and the driver, causing it to translate along the piston rod axis during dose setting '383 Patent, FIG. 1 '383 Patent, col. 3:56-64 A party may argue the term should be limited to such a threaded, translating structure.

The Term: "pivot bearing" (from '893 Patent, claim 1)

• Context and Importance: This term defines the key friction-reducing feature of the push button connection. Whether the accused device infringes claim 1 will likely depend on whether the contact point between its push button and internal driving part can be construed as a "pivot bearing."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent's summary describes the invention's object as providing a connection that "minimizes the forces a user must apply," which is achieved by "forming a pivot bearing between the two parts" '893 Patent, col. 2:40-45 This functional description may support a broader definition that includes any interface designed to reduce rotational friction under an axial load.
  • Evidence for a Narrower Interpretation: The detailed description states, "The bottom of the bore is preferable formed with a pivot. This pivot bears on a surface of the protrusion thus forming a pivot bearing" '893 Patent, col. 2:29-32 Embodiments show a specific pointed structure (18) creating point contact (Compl., Ex. C, '893 Patent, FIG. 1). A party may argue that "pivot bearing" is limited to a structure that creates this type of minimized surface-area contact, not just any flat-surface interface.

VI. Other Allegations

Indirect Infringement

The complaint is premised on the act of filing the ANDA as an act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶32 Compl. ¶38 Compl. ¶44 The complaint also alleges that upon FDA approval, Sun's commercial activities will constitute direct and/or indirect infringement under 35 U.S.C. §§ 271(a) and/or (b) Compl. ¶44

Willful Infringement

The complaint alleges that Sun was aware of the patents-in-suit when it submitted its ANDA, which included Paragraph IV certifications against them Compl. ¶36 Compl. ¶42 Compl. ¶65 This alleged pre-suit knowledge forms the basis for Plaintiff's request for a finding of an exceptional case and an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶36 Compl. ¶42 Compl. ¶65

VII. Analyst's Conclusion: Key Questions for the Case

• A key evidentiary question will be one of mechanical correspondence: Does the device described in Sun's ANDA, which has not yet been produced for sampling Compl. ¶27, actually contain the specific interacting components-such as a translating "limiter" and a redundant "safety mechanism"-that are recited in the asserted claims of the '383 and '953 patents, or is there a fundamental mismatch in its technical operation for limiting the dose?
• A central issue of claim construction will be one of definitional scope: Can the term "pivot bearing" in the '893 patent, described in embodiments as a point-contact structure, be construed to cover the specific mechanical interface between the push button and driving part in Sun's Device, or does the accused design utilize a different, non-infringing type of connection?
• Given the context of ANDA litigation, a core procedural question will be one of technical comparison: How will the court resolve the infringement dispute based on a comparison of the paper record (the ANDA schematics and descriptions) and any subsequently produced physical samples against the court's construction of the patent claims, which govern mechanical devices with precise structural and functional limitations?